Format

Send to

Choose Destination
Cell Cycle. 2015;14(18):2985-95. doi: 10.4161/15384101.2014.989114.

The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.

Author information

1
a Department of Medical Genetics ; University of Antwerp ; Antwerp , Belgium.
2
i Present address: Department of Biological Sciences ; Hunter College; City University of New York ; New York , NY USA.
3
b VIB Department of Molecular and Developmental Genetics ; Molecular Neurobiology; Catholic University Leuven ; Leuven , Belgium.
4
j Present address: Seaver Autism Centre for Research and Treatment; Icahn School of Medicine at Mount Sinai ; New York , NY USA.
5
c Department of Clinical Genetics ; Erasmus MC Rotterdam ; Rotterdam , The Netherlands.
6
d Department of Molecular and Human Genetics ; Baylor College of Medicine; One Baylor Plaza ; Houston , TX USA.
7
e Department of Biomedicine and Prevention ; University of Rome Tor Vergata ; Rome , Italy.
8
f Laboratory of Neurochemistry and Behaviour; Institute Born-Bunge ; Department of Biomedical Sciences ; University of Antwerp ; Antwerp , Belgium.
9
g Memory clinic; Department of Neurology ; Middelheim General Hospital; ZNA ; Antwerp , Belgium.
10
h Department of Neurology and Alzheimer Research Centre ; University Medical Centre; Groningen , The Netherlands.

Abstract

Previous research indicates that the GABAAergic system is involved in the pathophysiology of the fragile X syndrome, a frequent form of inherited intellectual disability and associated with autism spectrum disorder. However, the molecular mechanism underlying GABAAergic deficits has remained largely unknown. Here, we demonstrate reduced mRNA expression of GABAA receptor subunits in the cortex and cerebellum of young Fmr1 knockout mice. In addition, we show that the previously reported underexpression of specific subunits of the GABAA receptor can be corrected in YAC transgenic rescue mice, containing the full-length human FMR1 gene in an Fmr1 knockout background. Moreover, we demonstrate that FMRP directly binds several GABAA receptor mRNAs. Finally, positive allosteric modulation of GABAA receptors with the neurosteroid ganaxolone can modulate specific behaviors in Fmr1 knockout mice, emphasizing the therapeutic potential of the receptor.

KEYWORDS:

FMRP mRNA target; Fmr1 knockout mouse; GABAA receptor; fragile X syndrome; ganaxolone; targeted therapy

PMID:
25790165
PMCID:
PMC4827888
DOI:
10.4161/15384101.2014.989114
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center